Skip to main content
Erschienen in: Clinical Research in Cardiology 2/2017

16.11.2016 | Original Paper

Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation

verfasst von: Philipp Ruile, Nikolaus Jander, Philipp Blanke, Simon Schoechlin, Jochen Reinöhl, Michael Gick, Juergen Rothe, Mathias Langer, Jonathon Leipsic, Heinz-Joachim Buettner, Franz-Josef Neumann, Gregor Pache

Erschienen in: Clinical Research in Cardiology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

After transcatheter aortic valve implantation, early leaflet thickening, presumably reflecting thrombus, has recently been described on computed tomography angiography (CTA) in ~10% of the patients. We sought to investigate the impact of the antithrombotic regimen on the course of leaflet thickening.

Methods

The study comprised 51 patients with leaflet thickening. Based on the time period, patients without an established indication for anticoagulation were put on phenprocoumon plus clopidogrel for at least 3 months or on dual antiplatelet therapy with aspirin and clopidogrel. Follow-up CTAs were evaluated for leaflet restriction, assessed by four-point-grading score, and maximal thickness.

Findings

The anticoagulation and the dual antiplatelet therapy group comprised 29 and 22 patients, respectively. After a median of 86 days, we obtained follow-up CTAs in 22 patients on anticoagulation and in 16 patients on dual antiplatelet therapy. Leaflet thickening progressed in 11 on dual antiplatelet therapy, but always regressed onanticoagulation. The course of leaflet restriction and maximal thickness was significantly different between the two groups (P < 0.001): in the dual antiplatelet therapy group, maximal thickness increased by a mean of 1.37 ± 1.67 mm (P = 0.005) and leaflet restriction score by a median 1[quartiles 0;2] (P = 0.013), whereas in the anticoagulation group, maximal thickness regressed by 2.57 ± 1.52 mm (P < 0.001) and leaflet restriction score decreased by 1[−4;0] (P = 0.001). After a median of 91 days after discontinuation of anticoagulation, CTA performed in ten patients revealed a significant recurrent increase in leaflet restriction score and maximal thickness (P = 0.023, P = 0.007). In the entire cohort, changes in leaflet restriction correlated significantly with changes in transvalvular pressure gradients (r = 0.511, P < 0.001).

Interpretation

The course of leaflet restriction was fundamentally different depending on the presence or absence of anticoagulation, with consistent regression under phenprocoumon, but mostly progression under antiplatelet therapy alone. Changes in leaflet restriction were associated with changes in transvalvular pressure gradients.
Literatur
1.
Zurück zum Zitat Pache G, Blanke P, Zeh W et al (2013) Cusp thrombosis after transcatheter aortic valve replacement detected by computed tomography and echocardiography. Eur Heart J 34:3546CrossRefPubMed Pache G, Blanke P, Zeh W et al (2013) Cusp thrombosis after transcatheter aortic valve replacement detected by computed tomography and echocardiography. Eur Heart J 34:3546CrossRefPubMed
3.
Zurück zum Zitat Makkar RR, Fontana G, Jilaihawi H et al (2015) Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373:2015–2024CrossRefPubMed Makkar RR, Fontana G, Jilaihawi H et al (2015) Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373:2015–2024CrossRefPubMed
5.
Zurück zum Zitat Hansson NC, Grove EL, Andersen HR et al (2016) Transcatheter aortic heart valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol 68(19):2059–2069CrossRefPubMed Hansson NC, Grove EL, Andersen HR et al (2016) Transcatheter aortic heart valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol 68(19):2059–2069CrossRefPubMed
6.
Zurück zum Zitat Cota L, Stabile E, Agrusta M et al (2013) Bioprostheses “thrombosis” after transcatheter aortic valve replacement. J Am Coll Cardiol 61:789–791CrossRefPubMed Cota L, Stabile E, Agrusta M et al (2013) Bioprostheses “thrombosis” after transcatheter aortic valve replacement. J Am Coll Cardiol 61:789–791CrossRefPubMed
7.
Zurück zum Zitat Córdoba-Soriano JG, Puri R, Amat-Santos I et al (2015) Valve thrombosis following transcatheter aortic valve implantation: a systematic review. Rev Esp Cardiol Engl Ed 68:198–204CrossRefPubMed Córdoba-Soriano JG, Puri R, Amat-Santos I et al (2015) Valve thrombosis following transcatheter aortic valve implantation: a systematic review. Rev Esp Cardiol Engl Ed 68:198–204CrossRefPubMed
8.
Zurück zum Zitat Leetmaa TH, Poulsen SH, Nörgaard BL et al (2014) Two cases of thrombotic stenosis in SAPIEN XT valves after transapical implantation. EuroIntervention 10:270CrossRefPubMed Leetmaa TH, Poulsen SH, Nörgaard BL et al (2014) Two cases of thrombotic stenosis in SAPIEN XT valves after transapical implantation. EuroIntervention 10:270CrossRefPubMed
9.
Zurück zum Zitat Lancellotti P, Radermecker MA, Weisz SH et al (2013) Subacute transcatheter CoreValve thrombotic obstruction. Circ Cardiovasc Interv 6:e32–e33CrossRefPubMed Lancellotti P, Radermecker MA, Weisz SH et al (2013) Subacute transcatheter CoreValve thrombotic obstruction. Circ Cardiovasc Interv 6:e32–e33CrossRefPubMed
10.
Zurück zum Zitat Latib A, Messika-Zeitoun D, Maisano F et al (2013) Reversible edwards sapien XT dysfunction due to prosthesis thrombosis presenting as early structural deterioration. J Am Coll Cardiol 61:787–789CrossRefPubMed Latib A, Messika-Zeitoun D, Maisano F et al (2013) Reversible edwards sapien XT dysfunction due to prosthesis thrombosis presenting as early structural deterioration. J Am Coll Cardiol 61:787–789CrossRefPubMed
11.
Zurück zum Zitat Pislaru SV, Hussain I, Pellikka PA et al (2015) Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 47(4):725–732CrossRefPubMed Pislaru SV, Hussain I, Pellikka PA et al (2015) Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 47(4):725–732CrossRefPubMed
12.
Zurück zum Zitat Butnaru A, Shaheen J, Tzivoni D et al (2013) Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 112:1439–1444CrossRefPubMed Butnaru A, Shaheen J, Tzivoni D et al (2013) Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 112:1439–1444CrossRefPubMed
13.
Zurück zum Zitat Jander N, Kienzle R-P, Kayser G et al (2012) Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol 109:257–262CrossRefPubMed Jander N, Kienzle R-P, Kayser G et al (2012) Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol 109:257–262CrossRefPubMed
14.
Zurück zum Zitat Jander N, Pache G, Henschke S et al (2013) Diagnosis of obstructive thrombosis in a porcine bioprosthesis in the aortic position by contrast-enhanced ECG-gated computer tomography. Eur Heart J 34:1357CrossRefPubMed Jander N, Pache G, Henschke S et al (2013) Diagnosis of obstructive thrombosis in a porcine bioprosthesis in the aortic position by contrast-enhanced ECG-gated computer tomography. Eur Heart J 34:1357CrossRefPubMed
15.
Zurück zum Zitat Ye J, Cheung A, Lichtenstein SV, Carere RG, Thompson CR, Pasupati S, Webb JG (2006) Transapical aortic valve implantation in humans. J Thorac Cardiovasc Surg 131:1194–1196CrossRefPubMed Ye J, Cheung A, Lichtenstein SV, Carere RG, Thompson CR, Pasupati S, Webb JG (2006) Transapical aortic valve implantation in humans. J Thorac Cardiovasc Surg 131:1194–1196CrossRefPubMed
16.
Zurück zum Zitat Webb JG, Chandavimol M, Thompson CR et al (2006) Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 113:842–850CrossRefPubMed Webb JG, Chandavimol M, Thompson CR et al (2006) Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 113:842–850CrossRefPubMed
17.
Zurück zum Zitat Jander N, Sommer H, Pingpoh C et al (2015) The porcine valve type predicts obstructive thrombosis beyond the first three postoperative months in bioprostheses in the aortic position. Int J Cardiol 15(199):90–95CrossRef Jander N, Sommer H, Pingpoh C et al (2015) The porcine valve type predicts obstructive thrombosis beyond the first three postoperative months in bioprostheses in the aortic position. Int J Cardiol 15(199):90–95CrossRef
18.
Zurück zum Zitat Kappetein AP, Head SJ, Généreux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 33:2403–2418CrossRefPubMed Kappetein AP, Head SJ, Généreux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 33:2403–2418CrossRefPubMed
19.
Zurück zum Zitat Del Trigo M, Muñoz-Garcia AJ, Wijeysundera HC et al (2016) Incidence, timing, and predictors of valve hemodynamic deterioration after transcatheter aortic valve replacement: multicenter registry. J Am Coll Cardiol 67:644–655CrossRefPubMed Del Trigo M, Muñoz-Garcia AJ, Wijeysundera HC et al (2016) Incidence, timing, and predictors of valve hemodynamic deterioration after transcatheter aortic valve replacement: multicenter registry. J Am Coll Cardiol 67:644–655CrossRefPubMed
20.
Zurück zum Zitat Mack MJ, Douglas PS, Holmes DR (2016) Shedding more light on valve thrombosis after transcatheter aortic valve replacement∗. J Am Coll Cardiol 67:656–658CrossRefPubMed Mack MJ, Douglas PS, Holmes DR (2016) Shedding more light on valve thrombosis after transcatheter aortic valve replacement∗. J Am Coll Cardiol 67:656–658CrossRefPubMed
21.
Zurück zum Zitat Greason KL, Mathew V, Sarano ME et al (2013) Early transcatheter aortic valve thrombosis. J Card Surg 28:264–266CrossRefPubMed Greason KL, Mathew V, Sarano ME et al (2013) Early transcatheter aortic valve thrombosis. J Card Surg 28:264–266CrossRefPubMed
22.
Zurück zum Zitat Tay E, Gurvitch R, Wijesinghe N et al (2011) Valve thrombosis after transcatheter heart valve implantation. EuroIntervention 7:170–171CrossRefPubMed Tay E, Gurvitch R, Wijesinghe N et al (2011) Valve thrombosis after transcatheter heart valve implantation. EuroIntervention 7:170–171CrossRefPubMed
23.
Zurück zum Zitat Trepels T, Martens S, Doss M et al (2009) Thrombotic restenosis after minimally invasive implantation of aortic valve stent. Circulation 120:e23–e24CrossRefPubMed Trepels T, Martens S, Doss M et al (2009) Thrombotic restenosis after minimally invasive implantation of aortic valve stent. Circulation 120:e23–e24CrossRefPubMed
Metadaten
Titel
Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation
verfasst von
Philipp Ruile
Nikolaus Jander
Philipp Blanke
Simon Schoechlin
Jochen Reinöhl
Michael Gick
Juergen Rothe
Mathias Langer
Jonathon Leipsic
Heinz-Joachim Buettner
Franz-Josef Neumann
Gregor Pache
Publikationsdatum
16.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 2/2017
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-016-1052-3

Weitere Artikel der Ausgabe 2/2017

Clinical Research in Cardiology 2/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.